Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through debt or equity in the current call. Capex plans detailed: INR 250 crores for FY '26, primarily growth capex (INR 210 crores) and maintenance capex (INR 40 crores). FY '27 and FY '28 capex expected to be mostly maintenance capex; no new major capex announced beyond current plans. No stated plans for additional fundraising; focus is on utilizing existing resources for ongoing projects like electrolyte additives plant and South Korea JV. Business expansion appears funded through internal accruals and existing investments, as no queries or respons

Any current/future capex/capital investment/strategic investment?

FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth. Major growth capex includes INR 180 crores for electrolyte additive plant at Jaghadia and INR 30 crores for pilot plant at Sachin. Electrolyte additive capex expected to complete by Q4 FY '26 and start contributing from Q4 FY '26, fully ramping by FY '27. South Korea JV (Indichem) capex underway, commercial production expected in H2 FY '27; Acutaas holds 75% stake. Beyond FY '26, all planned growth capex expected to be completed; future capex to be mainly maintenance. Additional ca

Future growth expectations in sales/revenue/volumes?

The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. Higher growth is expected from the CDMO business segment compared to traditional Pharma Intermediates. Electrolyte additives segment is expected to start contributing from Q4 FY '26 and more significantly in FY '27, with full visibility on capex and products. Semiconductor JV in South Korea is projected to start commercial production in H2 FY '27, contributing to revenue thereafter. Specialty Chemicals segment is expected to grow around 10-15% in FY '26.

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). Electrolyte additive plant commissioning by Q4 FY '26 and full commercial cont

Current/ Expected Orderbook/ Pending Orders?

Validation batches for new CDMO contracts have been sent during the quarter. Commercial production for these new CDMO products is expected to start by the last quarter of FY '26, subject to regulatory approvals. Full visibility exists for the CDMO business for the current year and projections for the next years, indicating a healthy order book. The Block 3 at Ankleshwar, commissioned last year, is operational and catering to projected customer requirements. For electrolyte additives, the planned capacity (2,000 metric tons each for VC and FEC) is based on signed contracts, providing full visib

IN US

Sale is live|00:00:00left today

Acutaas Chemicals LtdQ3 FY25Pharmaceuticals & Biotechnology

Acutaas Chemicals Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,145P/E: 62.8Market Cap: ₹22.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26.
→Higher growth is expected from the CDMO business segment compared to traditional Pharma Intermediates.
→Electrolyte additives segment is expected to start contributing from Q4 FY '26 and more significantly in FY '27, with full visibility on capex and products.
→Semiconductor JV in South Korea is projected to start commercial production in H2 FY '27, contributing to revenue thereafter.
→Specialty Chemicals segment is expected to grow around 10-15% in FY '26.
→No specific revenue disclosure for new segments, but significant growth drivers identified in CDMO, battery chemicals, and semiconductor chemicals in the coming years.
→Growth is supported by expanding product portfolio focusing on higher-margin products for sustainable growth.
→Capacity ramp-up, especially Block 3 and new plants, expected to enhance volumes gradually over 2-3 years.

Margin guidance

Category 3

→The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14).
→Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14).
→New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6).
→Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15).
→Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6).
→Capital expenditures focused on growth (INR 210 crores approx. in FY '26) with asset turns around 2.5x and payback periods of 3-3.5 years, supporting medium-term earnings expansion (Pages 11, 14).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No explicit mention of any new fundraising through debt or equity in the current call.
→Capex plans detailed: INR 250 crores for FY '26, primarily growth capex (INR 210 crores) and maintenance capex (INR 40 crores).
→FY '27 and FY '28 capex expected to be mostly maintenance capex; no new major capex announced beyond current plans.
→No stated plans for additional fundraising; focus is on utilizing existing resources for ongoing projects like electrolyte additives plant and South Korea JV.
→Business expansion appears funded through internal accruals and existing investments, as no queries or responses indicate fresh fund raises.

Order book

→Validation batches for new CDMO contracts have been sent during the quarter.
→Commercial production for these new CDMO products is expected to start by the last quarter of FY '26, subject to regulatory approvals.
→Full visibility exists for the CDMO business for the current year and projections for the next years, indicating a healthy order book.
→The Block 3 at Ankleshwar, commissioned last year, is operational and catering to projected customer requirements.
→For electrolyte additives, the planned capacity (2,000 metric tons each for VC and FEC) is based on signed contracts, providing full visibility on demand.
→Overall, multiple products and customers across segments maintain a diversified and robust order pipeline.
→The company is confident of sustaining a 25% revenue growth driven by existing and upcoming contracts.

Capex plans

Yes

→FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth.
→Major growth capex includes INR 180 crores for electrolyte additive plant at Jaghadia and INR 30 crores for pilot plant at Sachin.
→Electrolyte additive capex expected to complete by Q4 FY '26 and start contributing from Q4 FY '26, fully ramping by FY '27.
→South Korea JV (Indichem) capex underway, commercial production expected in H2 FY '27; Acutaas holds 75% stake.
→Beyond FY '26, all planned growth capex expected to be completed; future capex to be mainly maintenance.
→Additional capacity expansion in electrolyte additives possible depending on business development but no announcements yet.
→Asset turnover target from capex approximately 2.5x over about 3 years.

How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Acutaas Chemicals Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Acutaas Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio